Advanced Analysis Free Trading Signals Real Time Alerts

Impel NeuroPharma Stock Falls After Pricing Public Offering

Practice Stock Trading Your Capital Is At Risk
Updated: 10 Sep 2021

Impel NeuroPharma (NASDAQ: IMPL) shares are down premarket on Friday after it announced its $45 million public offering pricing.

The company is offering 3 million shares of its stock at a price of $15 per share. Before deducting expenses, the gross proceeds from the offering are expected to be $45.0 million.

In addition, Impel has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of stock at the offering price. The offering is expected to close on September 14.

new-recommended-broker-banner

Cowen and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.

Thursday saw the company's shares gain 27.25%, closing at $21.13 a day after it announced the public offering.

However, premarket on Friday has seen Impel shares resume their fall, currently trading at $18.35, down 13.87%

Only last week, Cowen analyst Ken Cacciatore raised the firm's price target on Impel NeuroPharma to $55 from $35, keeping an Outperform rating.

Should You Invest in Impel NeuroPharma Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 68 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .